Comment on SCHN. Although NUE announce the lower end of its earning prediction for 2Q, SCHN is not a steel producer and it should not be compared directly with NUE. Second, If you look at their June 5 report, you can predict the Schnitzer's sales are about double the reported values, moreover if you include their share of the joint venture which accounts for a significant share of profits to SCHN. http://library.corporate-ir.net/library/87/870/87090/items/155021/060905presentation.pdf Base on SCHN's potential future scrap demand, and SCHN's auto parts business, the 3Q for SCHN should be good. I analyse and predict the earning correctly consecutively for GMTN 10Q, LAZ 1Q, NGPS 2Q, KOMG 1Q this year.
News: JPM Reports 15.6% LAZ Stake (c) 2005 Dow Jones & Company, Inc. WASHINGTON (Dow Jones)--JPMorgan Chase & Co. (JPM) reported a 15.6% Class A stake in Lazard Ltd. (LAZ), according to a Schedule 13G filed Monday with the Securities and Exchange Commission. JPMorgan, one of the underwriters for Lazard's initial public offering in May, beneficially owns 5.86 million Lazard Class A common shares, the filing said. JPMorgan reported its stake on a form designated for passive investors, or those not seeking to change or influence a company's operation. Shares of Lazard closed Monday at $23.67 each. LAZ definately a Strong buy, Fidelity require 15% stake of LAZ three weeks ago and give the target $27. Now JPM bought another 15.6% stake. Take a look at how many merge & acquicition cases these days (almost every day), you can figure out the M&A business for LAZ.
CD, CSH new high here. I called CD $19.7, CSH under $15. Still hold these two stocks. Add more LAZ here, from its TA, bullish chart and target is as those investment bank gives"close $27"
LAZ volume alert: in the last 30 min, volume increase suddently to 75K. You can see this by checking minute chart with volume. Just some observe.
RHAT strong buy, earning at 5 This is the article from Valueline: We forecast continued solid revenue growth of about 40% for Red Hat in fiscal 2005 (ends February, 2006), following the strong 56% advance in 2004. Enterprise subscriptions should remain strong, supported by robust demand for Linux software. Margins may be hindered temporarily by increased hiring in sales and service to support the company's international expansion plans, but the impact should be offset by rising volume and a favorable shift in the product mix to subscriptions (which have 90% gross margins). After figuring in a higher tax rate (10%, versus zero), the gain in earnings is estimated at roughly 25%. The Linux operating system (OS) is projected to be the fastest-growing server OS during the next 3 to 5 years, expanding its market share from the current 19% to around 30%. The main reason behind this positive trend is the significant cost advantage of running Linux software on Intel-based hardware, compared to proprietary Unix. As the #1 vendor of Linux software, Red Hat should especially benefit from this trend. Visibility into future revenues is enhanced by a conservative subscription model, whereby new bookings go on the balance sheet as deferred revenues, and then flow to the income statement over the life of the sales contract. At the end of fiscal 2004, short-term deferred revenues equaled $109 million, comprising 40% of our 2005 revenue estimate. Red Hat faces competition from Novell SUSE, the #2 Linux vendor, and from Sun Microsystems, a major Unix company. Novell appears to be more of a threat in the small-to-medium business segment, while the company is very strong in the large-enterprise market. And Sun is beginning to offer its Unix OS (Solaris) on low-cost Intel servers. So far, RHAT's bookings have remained healthy, despite the competition. This neutrally ranked stock has excellent capital appreciation potential out to 2008-2010, based on the growing demand projected for the Linux software market and RHAT`s leading competitive position. However, the shares carry a Below-Average Safety rank. Competition and patent litigation are also concerns. May 27, 2005
Two good news for LAZ, $25 WPP CEO Sorrell In Talks To Join Lazard Board - FT 65 words 30 June 2005 05:21 pm Dow Jones International News English (c) 2005 Dow Jones & Company, Inc. NEW YORK (Dow Jones)--Sir Martin Sorrell, chief executive of WPP Group PLC (WPPGY), the world's second-biggest marketing services group, has been in talks to join the board of directors at Lazard Ltd. (LAZ), the investment bank, The Financial Times reported in an article on its Web site Thursday. [ 30-06-05 2221GMT ] Lazard to decide on Paris listing by end-2005 30 June 2005 05:55 am PARIS (AFX) - Lazard will decide by the end of 2005 if it is to list its shares in Paris as well as in New York, according to chief executive Bruce Wasserstein. In an interview with Le Figaro, Wasserstein added that the bank is not for sale. Lazard, listed in New York since May 5, is an 'independent bank and there is no reason for that to change,' he said. paris@afxnews.com
HLTH Target: $14-$16 WebMD (formerly Healtheon/WebMD) provides Internet-based healthcare information and services to facilitate connectivity and transactions among physicians, patients, payers, and other healthcare participants. Its platform allows for the secure exchange of information among the disparate systems used in the industry. Administrative services include patient enrollment, referrals and authorizations, diagnostic orders and results, clinical data retrieval, and claims processing. Valueline Upgrade HLTH to Timeness 1 for strong buy for the next 12 month on June 24. We have raised our 2005 revenue target for WebMD. Recent acquisitions in the company's Business Services group are adding to this segment's top line. Moreover, it is now able to offer a more complete solution for managing the health claims/payment process, and so it is probable that Business Services will benefit in terms of contract signings. At this point, we estimate that the group's revenue should advance by some 10%, up from 7.5% and adding about $20 million to WebMD's overall tally. Elsewhere, we have bumped up our sales target for WebMD Health by around $10 million, while leaving those for Practice Services and Porex unchanged. Earnings should continue progressing at a fast pace this year. WebMD has substantially raised its forecast for 2005 to a range of between $0.20 and $0.25 a share (GAAP). Accordingly, we have moved our estimate up by $0.08 a share, to the center of the current band. The reasoning behind the increase is underpinned by the potential for a higher margin in Business Services, reflecting more profitable contracts and reduced HIPAA-related expenses. In addition, it appears that operations may be running smoother at Practice Services, and that the profit margin may improve there, as well. The company has filed a registration statement to offer 10%-14% of WebMD Health to the public. In terms of revenue, the portal business is growing fast; it is also a good contributor to the bottom line. The IPO is a good idea for two reasons, in our view. First, it will give investors an opportunity to own shares in a profitable Internet business. Second, WebMD can use the proceeds to bolster its financial position (its 3.25% notes due 2007 were recently converted). At this writing, the registration statement was not yet effective. WebMD shares are currently top-ranked for Timeliness. The stock has found steady market support since our March report, most likely reflecting the better earnings prospects for 2005 and the potential that such growth may continue in coming years. Nonetheless, new commitments to this issue are best considered by risk-tolerant accounts. June 24, 2005